ONWARD MEDICAL BV EO -12 (F:63E) — Market Cap & Net Worth
Market Cap & Net Worth: ONWARD MEDICAL BV EO -12 (63E)
ONWARD MEDICAL BV EO -12 (F:63E) has a market capitalization of $169.27 Million (€144.78 Million) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #17163 globally and #1618 in its home market, demonstrating a -12.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONWARD MEDICAL BV EO -12's stock price €2.59 by its total outstanding shares 56008526 (56.01 Million).
ONWARD MEDICAL BV EO -12 Market Cap History: 2021 to 2026
ONWARD MEDICAL BV EO -12's market capitalization history from 2021 to 2026. Data shows change from $654.14 Million to $169.27 Million (-29.00% CAGR).
ONWARD MEDICAL BV EO -12 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONWARD MEDICAL BV EO -12's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 63E by Market Capitalization
Companies near ONWARD MEDICAL BV EO -12 in the global market cap rankings as of May 4, 2026.
Key companies related to ONWARD MEDICAL BV EO -12 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ONWARD MEDICAL BV EO -12 Historical Marketcap From 2021 to 2026
Between 2021 and today, ONWARD MEDICAL BV EO -12's market cap moved from $654.14 Million to $ 169.27 Million, with a yearly change of -29.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €169.27 Million | -40.44% |
| 2025 | €284.18 Million | -25.17% |
| 2024 | €379.78 Million | +96.61% |
| 2023 | €193.17 Million | -52.34% |
| 2022 | €405.32 Million | -38.04% |
| 2021 | €654.14 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of ONWARD MEDICAL BV EO -12 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $169.27 Million USD |
| MoneyControl | $169.27 Million USD |
| MarketWatch | $169.27 Million USD |
| marketcap.company | $169.27 Million USD |
| Reuters | $169.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more